[EN] MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS MACROCYCLIQUES DE 6-CHLORO-7-PYRAZOL-4-YL-1H-INDOLE-2-CARBOXYLATE ET 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE 1,3-PONTÉS EN TANT QU'INHIBITEURS DE MCL-1 POUR LE TRAITEMENT DU CANCER
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2022171782A1
公开(公告)日:2022-08-18
The present invention relates to compounds of formula (I) wherein XI is as myeloid cell leukemia-1 (MCL-1) inhibitors for the treatment of cancer, such as e.g. prostate, lung, pancreatic, breast, ovarian, and cervical cancer, melanoma, B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). An exemplary compound is e.g. compound 1
本发明涉及式(I)的化合物,其中XI为髓系细胞白血病-1(MCL-1)抑制剂,用于治疗癌症,例如前列腺癌、肺癌、胰腺癌、乳腺癌、卵巢癌、宫颈癌、黑色素瘤、B细胞慢性淋巴细胞白血病(CLL)、急性髓系白血病(AML)和急性淋巴细胞白血病(ALL)。其中一种示例化合物为化合物1。